Anastrozole and Enclomiphene Interaction: Monitor | Peptide Database

Join others researching PEG-MGF — share findings, ask questions, and learn from real experiences Modified IGF-1 variant with PEG attachment extending half-life from minutes to hours. Activates muscle satellite cells following mechanical stress or injury. Activates muscle satellite stem cells via receptor binding, stimulating MAPK/ERK signaling. Enhances protein synthesis and promotes muscle fiber repair. E-peptide domain exhibits distinct activity from mature IGF-1.

FDA-approved first-line treatment for excessive daytime sleepiness associated with narcolepsy. Significantly reduces unintended sleep episodes and improves the ability to sustain wakefulness throughout the day. FDA-approved for excessive sleepiness in individuals who work non-traditional hours (night shifts, rotating shifts). Taken 1 hour before the start of the work shift to maintain alertness during the shift. FDA-approved as adjunctive therapy for residual excessive daytime sleepiness in patients with obstructive sleep apnea who are already using CPAP but still experience daytime somnolence. Does not treat the underlying airway obstruction. Well-documented improvements in sustained attention, vigilance, and concentration during prolonged tasks. Benefits are most pronounced under conditions of sleep deprivation or fatigue, but also observed in well-rested individuals performing demanding cognitive work. Improvements in planning, decision-making, and cognitive flexibility observed across multiple studies. Effects are more consistent and reliable in sleep-deprived populations than in well-rested individuals. Modest improvements in working memory tasks, particularly in individuals experiencing fatigue or sleep deficit. Effects in well-rested, high-baseline individuals are less consistent. Used off-label for attention-deficit/hyperactivity disorder. Some studies show improvements in attention and impulsivity comparable to methylphenidate, though modafinil is not FDA-approved for this indication. FDA declined approval for pediatric ADHD due to skin reaction concerns. Investigated as an adjunct to antidepressants for treatment-resistant fatigue and cognitive symptoms in major depressive disorder. May improve residual sleepiness and cognitive dullness that persist despite adequate antidepressant response. Used off-label for fatigue associated with multiple sclerosis, one of the most disabling symptoms of the disease. Evidence is mixed, with some patients reporting meaningful improvement in energy and daily functioning.